Niklaus Meier

Wissenschaftlicher Mitarbeiter

Health Technology Assessment

Medikamentenpreise

Health Technology Assessment

Gesundheitsökonomie

Kosten-Wirksamkeitsanalysen

EU Horizon 2020 ENDOSCAPE (Grant agreement No. 825730)

Barbier, M. C., Fengler, A., Pardo, E., Bhadhuri, A., Meier, N., & Gautschi, O. (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland (Vol. 41, Issue 12). Springer. https://doi.org/10.24451/arbor.20301

Meier, N., Fuchs, H., Galactionova, K., Hermans, C., Pletscher, M., & Schwenkglenks, M. (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany (Vol. 8, Issue 3). Springer. https://doi.org/10.24451/arbor.21790

Trottmann, M., Blozik, E., Hilbig, M., LoVerdi, D., Pedruzzi, M., Scherer, T., Weiss, M., Pletscher, M., & Meier, N. (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data (Vol. 153, Issue 9). EMH Schweizerischer Aerzteverlag. https://doi.org/10.24451/arbor.20303

Swiss School of Public Health

Swiss Society of Health Economics